Details of the Drug Combination

General Information of Drug Combination (ID: DC6ES9O)

Drug Combination Name
Daidzin Arfolitixorin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Daidzin   DMFCMPS Arfolitixorin   DMIXMYK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 9.88
Bliss Independence Score: 9.88
Loewe Additivity Score: 11.74
LHighest Single Agent (HSA) Score: 11.82

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Daidzin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mitochondrial aldehyde dehydrogenase (ALDH2) TTFLN4T ALDH2_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Daidzin Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [4]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Increases Expression [4]
------------------------------------------------------------------------------------
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Intestinal bacteria activate estrogenic effect of main constituents puerarin and daidzin of Pueraria thunbergiana. Biol Pharm Bull. 2006 Dec;29(12):2432-5. doi: 10.1248/bpb.29.2432.